Welcome to our dedicated page for GMRBV SEC filings (Ticker: GMRBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GMRBV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GMRBV's regulatory disclosures and financial reporting.
Chiron Real Estate Inc. intends to offer up to $75,000,000 of 8.00% Series B Cumulative Redeemable Preferred Stock in an at-the-market offering under a Sales Agreement dated March 12, 2026.
The offering may be sold through agents or directly to agents as principals, with agents entitled to up to 2.0% of gross proceeds. Net proceeds are intended to be contributed to the Operating Partnership in exchange for Series B Preferred OP Units and used for general corporate purposes, which may include funding acquisitions and repaying borrowings under the Credit Facility.
Chiron Real Estate Inc. is registering up to $288,010,090 of common stock offered under an amended at-the-market sales agreement dated March 12, 2026, reflecting $11,989,910 previously sold under the program and an original program capacity of $300,000,000.
The supplement permits sales through multiple Agents and forward sale arrangements with specified Forward Purchasers and Forward Sellers, and describes settlement options (physical, cash or net share) and related underwriting-style compensation (up to 2.0%). Proceeds contributed to the Operating Partnership may repay Credit Facility borrowings, fund acquisitions or be used for general corporate purposes.
Chiron Real Estate Inc. entered into a Master Note and Guaranty Agreement with NYL Investors LLC and certain affiliates, creating an uncommitted senior note facility for its operating partnership. The facility permits issuance of senior unsecured notes in one or more series with an aggregate outstanding principal of up to $150.0 million.
Notes may be issued for up to three years from the agreement’s effective date, subject to earlier termination events, and each series will mature within ten years of issuance. Each issuance must be at least $10.0 million, with interest set at issuance as a spread over U.S. Treasuries and paid quarterly or semi-annually. The operating partnership may prepay the notes, subject to a customary make-whole amount, and the notes rank equally with its other senior unsecured debt.
Chiron Real Estate Inc., formerly Global Medical REIT, is an internally managed healthcare REIT focused on physician group and health-system facilities. As of December 31, 2025, it owned 189 buildings with about 5.1 million leasable square feet and annualized base rent of roughly $118.8 million.
Total gross real estate investments were about $1.5 billion, with significant concentration in Texas, Florida, Ohio, Arizona, Pennsylvania and Illinois, and top three tenants providing 18.1% of rent. The company uses a leveraged, SOFR-based credit facility, interest rate swaps, and a joint venture with Heitman, and highlights extensive regulatory, reimbursement, tenant credit, climate, cybersecurity and refinancing risks while seeking to maintain REIT tax status and regular dividends.
Chiron Real Estate Inc. reported that General Counsel and Secretary Jamie Allen Barber received equity-based awards in the form of LTIP Units in Chiron Real Estate LP, the company’s operating partnership. On February 24, 2026, Barber acquired 5,539 LTIP Units and an additional 2,025 LTIP Units at a price of $0.00 per unit as grant or award acquisitions.
According to the disclosures, one set of LTIP Units is scheduled to vest on February 24, 2029, subject to continued employment, while another grant had 50% of its LTIP Units become vested and nonforfeitable on February 24, 2026 after meeting market-based performance criteria, with the remaining 50% vesting on February 24, 2027. Vested LTIP Units that reach capital account parity may be exchanged for cash or, at the issuer’s election, for common stock on a one-for-one basis. The filing notes that all amounts reflect a 1-for-5 reverse stock split effective September 19, 2025.
KIERNAN ROBERT J reported acquisition or exercise transactions in this Form 4 filing.
Chiron Real Estate Inc. reported that its CFO and Treasurer, Robert J. Kiernan, received equity incentive awards in the form of LTIP Units in Chiron Real Estate LP, the company’s operating partnership. On February 24, 2026, he was granted 10,385 and 3,492 LTIP Units at a grant price of $0.00 per unit under the 2016 Equity Incentive Plan.
According to the award terms, all of these LTIP Units are scheduled to vest on February 24, 2029, if he remains employed through that date. Once vested and after achieving capital account parity under the partnership agreement, the LTIP Units may be exchanged for cash or, at the issuer’s election, for common stock on a one-for-one basis. The amounts shown already reflect the company’s prior 1‑for‑5 reverse stock split.
Chiron Real Estate Inc. reported that COO Holley Danica acquired LTIP Units in the company’s operating partnership through equity awards. On February 24, 2026, she received grants of 5,816 and 2,270 LTIP Units at a price of $0.00 per unit, held directly.
According to the accompanying descriptions, certain LTIP Units vest based on continued employment and market-based performance, with 50% vested and nonforfeitable as of February 24, 2026 and the remaining 50% scheduled to vest on February 24, 2027. Vested LTIP Units that achieve capital account parity may be exchanged for cash or, at the issuer’s election, for common stock on a one-for-one basis.
Chiron Real Estate Inc. reported that CIO Leon Alfonzo acquired two awards of LTIP Units (rights to buy) in Chiron Real Estate LP, totaling 10,385 and 3,273 units, at a stated price of $0.0000 per unit.
The LTIP Units are equity incentives under the 2016 Equity Incentive Plan and have no expiration date. All LTIP Units in one grant vest on February 24, 2029, subject to continued employment. For another LTIP award, the board determined that 50% became vested and nonforfeitable on February 24, 2026 based on market-based performance criteria as of December 31, 2025 and February 24, 2026, with the remaining 50% scheduled to vest on February 24, 2027. Once vested and after achieving capital account parity, LTIP Units may be exchanged for cash or, at the issuer’s election, for common stock on a one-for-one basis. The LTIP Unit amounts are reported on a post–1-for-5 reverse stock split basis following a split effective on September 19, 2025.
Chiron Real Estate Inc. director and CEO/President Mark Okey Decker Jr reported equity compensation awards in the form of LTIP Units in Chiron Real Estate LP, the company’s operating partnership. He acquired 16,616 LTIP Units and 4,702 LTIP Units, both at a stated price of $0.00 per unit.
According to the award terms, some LTIP Units vest fully on February 24, 2029 subject to continued employment, while another grant vests 50% on February 24, 2026 based on market-based performance criteria as of December 31, 2025 and February 24, 2026, and 50% on February 24, 2027. Once vested and after achieving capital account parity, these LTIP Units may be exchanged for cash or, at the company’s election, for common stock on a one-for-one basis and have no expiration date.
Chiron Real Estate Inc., formerly Global Medical REIT, reported 2025 results, updated its capital strategy and completed a corporate rebrand. For 2025, total revenue was $148.2 million and the company recorded a net loss of $6.9 million, driven in part by $13.0 million of property impairments.
FFO attributable to common stockholders and noncontrolling interest was $57.6 million ($3.97 per share and unit), while Core FFO reached $65.8 million ($4.53 per share and unit). Leverage was 44.4% at December 31, 2025, with $653.9 million of consolidated debt at a 3.74% weighted average interest rate and no maturities in 2026 or 2027.
The board kept the annualized common dividend at $3.00 per share but shifted to monthly payments, declaring $0.25 per share for each of April, May and June 2026. The company invested $7.1 million for a 49% interest in an active adult joint venture and set 2026 Core FFO guidance at $4.30 to $4.45 per share and unit. A key tenant, White Rock Medical Center, filed for Chapter 11, and Chiron carried a $1.4 million net receivable from its support efforts.